| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 24, 2026 12:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
MELBOURNE, Australia, March 24, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that a multi-year Joint Research Collaboration Agreement has been established with the Universities of Jaén (UJA) and Granada (UGR), Spain. This is the fifth agreement between Propanc and the universities over a seventeen-year period resulting in four patent families being filed, five peer reviewed publications accepted, numerous scientific presentations delivered, as well as two PhD's and a professorship awarded to membe
MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced highlights of PRP, its lead proenzyme therapy poised to potentially disrupt the $3 billion+ pancreatic cancer treatment market—one of oncology's most desperate battlegrounds with a grim 13% five-year survival rate. Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game:- >85% tumor growth inhibition demonstrated in preclinical pancreatic models - Forces malignant cells t
MELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that management has executed a service agreement with FyoniBio GmbH (formerly Glycotope, est. 2010), a German Contract Development Organization (CDO) based in Berlin for establishing and validating a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay. The objective is to quantify the Company's lead asset, PRP, consisting of two proenzymes trypsinogen and chymotrypsinogen, as well as their ac
MELBOURNE, Australia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported half yearly financial results as of December 31, 2025 (Year end June 30). Corporate and R&D Highlights Accelerates IP Momentum: Files Four Provisional Patent Applications – Strengthening Global Protection for Breakthrough Proenzyme Formulations Four provisional patent applications were filed with IP Australia detailing two new methods to treat resistant cancer and fibrosis, methods of producing synthetic try
EFFECT - Propanc Biopharma, Inc. (0001517681) (Filer)
S-1 - Propanc Biopharma, Inc. (0001517681) (Filer)
DEF 14C - Propanc Biopharma, Inc. (0001517681) (Filer)